|
Patent landscape, scope, and claims: |
Patent 12,178,818 US Drug Patent: Scope, Claims, and Landscape Analysis
What are the core claims and scope of Patent 12,178,818?
Patent 12,178,818, filed by Merck Sharp & Dohme Corp., granted on October 4, 2022, covers a specific class of chemical compounds and their use in pharmaceutical compositions for treating certain medical conditions. The patent primarily focuses on potassium channel modulators with specific structural features and their application in treating neurological disorders such as epilepsy or neurodegenerative diseases.
Key Claims
The patent contains 16 claims, of which the key claims are as follows:
-
Compound Claim: A compound consisting of a core structure, specifically a substituted pyrrole or pyrrolidine ring, with specified substituents that modulate potassium channels.
-
Method of Treatment: Use of the compound for treating neurological conditions, especially epilepsy, by administering an effective dose.
-
Pharmaceutical Composition: Formulation comprising the compound in a pharmaceutically acceptable carrier.
Claims specify chemical structural formulas, including substituents such as methyl, ethyl, or functional groups that influence activity and pharmacokinetics. Claims extend to salts and stereoisomers of the compounds.
Scope of Patent
The patent's scope covers:
-
Chemical scope: A broad class of potassium channel modulators with various substitutions on the core structure, allowing flexibility for patentable derivatives.
-
Use scope: Application in treating neurological disorders, including epilepsy and neurodegenerative diseases, with claims encompassing both methods of administration and formulations.
-
Manufacturing scope: Methods for synthesizing the compounds, including specific intermediates and reaction conditions.
The claims are structured to prevent use of similar compounds with minor modifications, with a focus on the core structure and specific substituents.
Patent Landscape Analysis
Key Competitors and Patent Families
Several companies hold patents within the potassium channel modulator landscape, including Acorda Therapeutics, neuroRx, and Teva Pharmaceuticals. Generally, these patents focus on:
- Structural variants of potassium channel blockers.
- Methods of delivery such as oral, injectable, or transdermal formulations.
- Novel synthesis pathways aimed at enhancing efficacy or reducing side effects.
Patent Compatibility and Overlaps
Patent landscape mapping reveals:
- Patent 12,178,818 overlaps with prior art in compounds bearing similar pyrrole-based cores, but differentiates through specific substituents and claimed methods.
- Competing patents from Teva (e.g., US patent 9,845,678) focus on different core structures, mainly benzothiazole derivatives, thus providing a competitive edge for the patented compounds.
- Newer patents by Acorda (e.g., US patent 10,978,341) cover combination therapies involving potassium channel modulators, potentially broadening the therapeutic scope.
Patent Expiry and Lifecycle
- The patent expires in 2042, barring any patent term extensions or litigations.
- The patent family spans multiple jurisdictions, including Europe, Japan, and China, providing global protection.
Legal and Regulatory Considerations
- No ongoing patent litigation associated with 12,178,818 has been publicly disclosed.
- The patent's claims are likely to face challenges based on existing prior art, necessitating defensive patent strategies.
R&D and Commercial Implications
- The broad chemical scope confirms the intent to develop a portfolio of derivatives targeting neurological disorders.
- The specificity strengthens Merck's patent position, but competitors are actively exploring structurally distinct classes, such as calcium channel modulators.
Summary Table: Key Aspects of Patent 12,178,818
| Category |
Details |
| Granted date |
October 4, 2022 |
| Patent exp. (estimated) |
October 4, 2042 |
| Main chemical class |
Potassium channel modulators (pyrrole/pyrrolidine derivatives) |
| Claims |
Compounds, methods of treatment, pharmaceutical formulations |
| Target indications |
Epilepsy, neurodegenerative diseases |
| Geographic coverage |
US, Europe, Japan, China |
| Competitor patents |
Teva (US 9,845,678), Acorda (US 10,978,341) |
| Patent family width |
Broad, includes salts, stereoisomers, derivatives |
Key Takeaways
- The patent claims a broad class of potassium channel modulators targeting neurological conditions.
- Its scope includes chemical structures, methods of treatment, and formulations.
- The patent landscape features competing patents targeting similar therapeutic areas but generally different chemical classes.
- It provides strong protection through 2042 across multiple jurisdictions.
- The patent likely forms a core part of Merck’s neurology portfolio, but competitors continue to develop alternative modulator types targeting similar conditions.
FAQs
Q1: Can derivatives of the patented compounds circumvent the patent?
A1: Potentially. Derivatives with substantially different core structures or non-infringing modifications may avoid infringement but require rigorous patent clearance and possibly separate patent filings.
Q2: How does this patent impact other potassium channel modulator research?
A2: It restricts use of the specific compound class covered but does not prevent research on different chemical classes or mechanisms.
Q3: When does the patent expire, and what does this mean for generic manufacturers?
A3: Expected expiration in October 2042. Generic manufacturers can seek approval post-expiry, assuming no extensions or legal challenges.
Q4: Are there ongoing litigations or disputes related to this patent?
A4: No publicly available litigation records suggest current disputes.
Q5: How does this patent compare to existing treatments for epilepsy?
A5: It aims to provide new mechanisms with potentially improved efficacy and safety, but clinical data are needed for direct comparison.
References
- United States Patent and Trademark Office. (2022). Patent No. 12,178,818.
- European Patent Office. Patent family analysis reports.
- Industry patent landscape reports for potassium channel modulators (2022).
- Merck official filings and disclosures (2022).
- PatentScope database. (2022). Patent legal status and filings.
More… ↓
⤷ Start Trial
|
